IGM Biosciences, Inc.

IGM Biosciences, Inc. is pioneering a new class of antibody medicines for the treatment of autoimmune and inflammatory diseases. By leveraging the greater binding power of the IgM antibody structure compared to the IgG structure, IGM has developed "super antibodies" offering novel therapeutic options and hope for patients. The company is at the forefront of research and development in engineered therapeutic IgM antibodies, aiming to expand and improve the qualities of these antibodies for medical use. Their innovative approach aims to open new pathways in treating diseases, particularly focusing on diseases like autoimmunity, where B-cell depletion is key.